Shirley, NY - Dec 29, 2025 - As a US-leading biotechnological company, Creative Bioarray proudly develops innovative technologies for the cell biology, pharmaceutical, biotechnology, and specialty ingredients markets, is always committed to supplying the best products and services with global manufacturing, development expertise, and advanced technologies. Recently, Creative Bioarray announced the launch of its sophisticated Fluorescent In Situ Hybridization (FISH)-based clonality analysis service, meticulously designed to assist clients in ensuring monoclonality assurance throughout the drug development process.
Current regulatory standards require biopharmaceutical cell lines to originate from a single cell ancestor; therefore, reliable cell line identification solutions are crucial. Creative Bioarray's newly launched service aims to facilitate the detailed identification of master cell banks (MCBs), working cell banks (WCBs), and end-of-production cells (EOPCs), providing high-quality data to help clients meet these compliance requirements.
Creative Bioarray's FISH-based clonality analysis utilizes advanced technology to ensure high-sensitivity detection of monoclonal cells within different cell populations. This service offers several key features to meet the unique needs of various cell lines, with a particular focus on CHO cell line characterization and HEK293 (human embryonic kidney) cells. Through precise visualization and quantitative analysis of clonal cell populations, clients can be confident that their final products meet regulatory standards and possess consistent efficacy.
The adoption of FISH technology facilitates comprehensive chromosome analysis. The service not only enables the identification of chromosomal abnormalities but also aids in evaluating chromosome integrity, thus providing valuable insights that are essential for CHO cell line characterization. The expert team at Creative Bioarray will conduct thorough analyses that include detailed reporting on genetic composition and stability throughout the production process.
"Another significant advantage of our FISH-based clonality analysis service is its rapid turnaround time. Results are typically available within four weeks, allowing Creative Bioarray to streamline the product development process while ensuring no compromise on product quality," said Hannah Cole, marketing director at Creative Bioarray. She also added, "Our service provides valuable insights into the evolution and genetic stability of clones during the manufacturing process. For clients looking to further optimize their processes, Creative Bioarray also offers other complementary services, including clonogenic assays of cells in vitro, which can further assess cell proliferation and viability."
By leveraging Creative Bioarray’s FISH-based clonality analysis services, clients can enhance their drug development pipelines, ensuring that their cell lines are thoroughly characterized and compliant with regulatory requirements.
About Creative Bioarray
Creative Bioarray stands at the cutting edge of biotechnology, delivering innovative solutions to researchers and biopharmaceutical companies worldwide. Committed to quality and regulatory compliance, Creative Bioarray continues to expand its repertoire of services to meet the evolving demands of the industry.
Media Contact
Company Name: Creative Bioarray
Contact Person: Hannah Cole
Email: Send Email
Phone: 16313868241
City: Shirley
State: New York 11967
Country: United States
Website: https://www.creative-bioarray.com/